Teva names new CFO and bulks up its opioid liability fund - PMLiVE
First generic version of Teva's Copaxone cleared by FDA - PMLiVE
Israel targets Teva over MS drug royalties
World MS Day, May 31, Marked by Teva's 'Life Moments with MS' Social Media Campaign
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
Federal Judge, Clarifying FCA Causation, Grants Feds Partial Summary Judgment | Law.com
EU says Teva blocked generics to MS drug Copaxone | pharmaphorum
Teva knocked as competition fears grow for MS drug
BCBS of Vermont sues Teva Pharmaceuticals over marketing for its MS drug Copaxone
Multiple Sclerosis Drugs Market Size, Share | CAGR of 3.8%
Teva loses key MS drug patent | Nature Reviews Drug Discovery
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
Teva | Partnership | Direct Relief
BCBS Vermont suing Teva Pharmaceuticals over MS drug marketing | Healthcare Finance News
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
FDA Nod to New MS Drug Spells Trouble for Teva - Haaretz Com - Haaretz.com
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Teva asks FDA to delay approval of Biogen's MS drug
PTAB invalidates three patents covering Teva's Copaxone, opens door for Mylan's generic version - IPWatchdog.com | Patents & Intellectual Property Law
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Teva steps up defence of key MS drug
Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies - 340B Report
